BACKGROUND: Idiopathic pulmonary fibrosis is a devastating disorder for which there is no effective treatment. Transforming growth factor (TGF)-beta plays a critical role in provoking fibrosis. Interleukin (IL)-10 is a potent immunosuppressive cytokine but its effect on the fibrosing process is unclear. A study was undertaken to examine whether IL-10 affects the production and activation of TGF-beta and thus can attenuate the fibrosis. METHODS: Mice were given an intratracheal injection of bleomycin. On day 1 or 14, IL-10 gene was delivered by rapid intravenous injection of Ringer's solution containing plasmid. Two weeks after the plasmid injection the mice were examined for fibrosis. The effect of IL-10 on TGF-beta production by alveolar macrophages was assessed. RESULTS: Even when delivered during the fibrosing phase, IL-10 gene significantly suppressed the pathological findings, hydroxyproline content, and production of both active and total forms of TGF-beta1 in the lung. Immunohistochemical analyses showed that alveolar macrophages were one of the major sources of TGF-beta1 and IL-10 diminished the intensity of the staining. IL-10 also suppressed the expression of alphaV beta6 integrin, a molecule that plays an important role in TGF-beta activation, on lung epithelial cells. Alveolar macrophages from bleomycin injected mice produced TGF-beta1 spontaneously ex vivo, which was significantly suppressed by treatment of the mice in vivo or by treatment of the explanted macrophages ex vivo with IL-10. CONCLUSION: IL-10 suppresses the production and activation of TGF-beta in the lung and thus attenuates pulmonary fibrosis, even when delivered in the chronic phase.
BACKGROUND:Idiopathic pulmonary fibrosis is a devastating disorder for which there is no effective treatment. Transforming growth factor (TGF)-beta plays a critical role in provoking fibrosis. Interleukin (IL)-10 is a potent immunosuppressive cytokine but its effect on the fibrosing process is unclear. A study was undertaken to examine whether IL-10 affects the production and activation of TGF-beta and thus can attenuate the fibrosis. METHODS:Mice were given an intratracheal injection of bleomycin. On day 1 or 14, IL-10 gene was delivered by rapid intravenous injection of Ringer's solution containing plasmid. Two weeks after the plasmid injection the mice were examined for fibrosis. The effect of IL-10 on TGF-beta production by alveolar macrophages was assessed. RESULTS: Even when delivered during the fibrosing phase, IL-10 gene significantly suppressed the pathological findings, hydroxyproline content, and production of both active and total forms of TGF-beta1 in the lung. Immunohistochemical analyses showed that alveolar macrophages were one of the major sources of TGF-beta1 and IL-10 diminished the intensity of the staining. IL-10 also suppressed the expression of alphaV beta6 integrin, a molecule that plays an important role in TGF-beta activation, on lung epithelial cells. Alveolar macrophages from bleomycin injected mice produced TGF-beta1 spontaneously ex vivo, which was significantly suppressed by treatment of the mice in vivo or by treatment of the explanted macrophages ex vivo with IL-10. CONCLUSION:IL-10 suppresses the production and activation of TGF-beta in the lung and thus attenuates pulmonary fibrosis, even when delivered in the chronic phase.
Authors: T E King; M I Schwarz; K Brown; J A Tooze; T V Colby; J A Waldron; A Flint; W Thurlbeck; R M Cherniack Journal: Am J Respir Crit Care Med Date: 2001-09-15 Impact factor: 21.405
Authors: Ganesh Raghu; Kevin K Brown; Williamson Z Bradford; Karen Starko; Paul W Noble; David A Schwartz; Talmadge E King Journal: N Engl J Med Date: 2004-01-08 Impact factor: 91.245
Authors: Joshua S Stoolman; Kevin M Vannella; Stephanie M Coomes; Carol A Wilke; Thomas H Sisson; Galen B Toews; Bethany B Moore Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-10-29 Impact factor: 5.464
Authors: Alice King; Swathi Balaji; Louis D Le; Timothy M Crombleholme; Sundeep G Keswani Journal: Adv Wound Care (New Rochelle) Date: 2014-04-01 Impact factor: 4.730
Authors: Valérie Besnard; Rania Dagher; Tania Madjer; Audrey Joannes; Madeleine Jaillet; Martin Kolb; Philippe Bonniaud; Lynne A Murray; Matthew A Sleeman; Bruno Crestani Journal: JCI Insight Date: 2018-03-08
Authors: Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm Journal: Oncoimmunology Date: 2016-06-27 Impact factor: 8.110
Authors: Mark S Wilson; Satish K Madala; Thirumalai R Ramalingam; Bernadette R Gochuico; Ivan O Rosas; Allen W Cheever; Thomas A Wynn Journal: J Exp Med Date: 2010-02-22 Impact factor: 14.307